In a 2014 study, specialists at UCLA asked over 153,000 first year undergraduates to assess their general emotional health — and it was rated at the lowest level that UCLA has ever documented. Researchers found that nearly one in ten students said they frequently felt depressed.
A separate study by the American College Health Association discovered that more than fifty percent of colleges students have experienced “overwhelming anxiety” sometime over the past year. More than 30 percent of them said they have felt so depressed “that it was difficult to function.” Nearly 40 percent said they “felt things were hopeless.”
Depression and anxiety with college students have been growing, and treatment of depression has been developing as well.
Analysts of a new study published in the most recent issue of Biological Psychiatry report effective decrease of depression symptoms in patients utilizing an innovative non-invasive method of vagus nerve stimulation, or VNS.
In spite of the increasing amount of neurostimulation approaches and medications available, leftover side effects may be both upsetting and incapacitating. Customary VNS is a neurostimulation procedure that has been utilized to diminish treatment-resistant symptoms of depression. Clinical trials proposed that it delivered relative advantage that developed over drawn out periods of time. Be that as it may, it was additionally expensive and required dangerous neurosurgery to embed the vagal nerve stimulators.
Drs. Peijing Rong and Jiliang Fang at the China Academy of Chinese Medical Sciences, working together with Jian Kong’s analysis group at Harvard Medical School, researched a new, altered type of VNS called transcutaneous VNS, which alternatively stimulates the vagus nerve through electrodes put into the ear.
Patients with major depressive disorder who volunteered for the study were either given transcutaneous VNS or placebo VNS and experienced a functional neuroimaging scan both before and after being treated for one month.
Contrasted with patients who were given placebo VNS, the patients who were given actual transcutaneous VNS displayed noteworthy improvement of their symptoms of depression. This change was linked with expanded functional connectivity amid the default mode system and precuneus and orbital prefrontal cortex, a critical system in the brain known that is changed in depression.
As claimed by Rong, this treatment can significantly downsize the asperity of depression and shows promise for use later on in the future.